This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Life Sciences Trends And Opportunities 2012-2015

NEW YORK, April 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Life Sciences Trends and Opportunities 2012-2015 http://www.reportlinker.com/p01075843/Global-Life-Sciences-Trends-and-Opportunities-2012-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Frost & Sullivan's global life sciences team analyzes the impact of important changes and key trends across the total pharmaceutical/biotechnology, diagnostics, and life sciences research industries. This research deliverable captures the global life sciences trends and opportunities for the period of 2012-2015, as supported by Frost & Sullivan's proprietary research and leading industry experts. Our global life sciences team is uniquely positioned to provide comprehensive analysis and guidance in the converging landscape. Topics include generics and biosimilars, emerging markets, pharmaceutical outsourcing, novel therapeutics, next generation diagnostics, research and development laboratories, and clinical laboratories.

TABLE OF CONTENTS

Executive Summary 6Daunting Challenges for the Pharmaceutical Industry 12Pharma's New Growth Strategies 17Curbing the Costs of Drug Development 32Lean Laboratories—Doing More With Less 37Novel Biomarker Discovery Leading to Novel Therapeutics 41Genetic Technologies are Integral to Healthcare 47Conclusions 52Appendix 55The Frost & Sullivan Story 65

List of ExhibitsLife Sciences Trends and Opportunities: Executive Summary, Global, 2012-2015 7Life Sciences Trends and Opportunities: Growth Areas Now and Developing, Global, 2012-2015 8Life Sciences Trends and Opportunities: Companies to Watch, Global, 2012-2015 9Life Sciences Trends and Opportunities: Competitive Companies Tracked by Frost & Sullivan, Global, 2012 10Life Sciences Trends and Opportunities: Future Outlook for Healthcare Compared to Present, Global, 2012-2015 11Life Sciences Trends and Opportunities: Key Mergers and Acquisitions by Pharmaceutical Companies, Global, 2010-2012 14Life Sciences Trends and Opportunities: Open Innovation—Pfizer and Novartis, Global, 2011 24Life Sciences Trends and Opportunities: Open Innovation—GlaxoSmithKline and Eli Lilly, Global, 2011 25Life Sciences Trends and Opportunities: Healthcare Expenditure, Global, 2010-2020 26Life Sciences Trends and Opportunities: Co-development Models, U.S., 2012 36Non-Invasive Prenatal Testing Market: Level of Agreement that NIPT Should Replace Maternal Serum Screen, U.S., 2012 51Life Sciences Trends and Opportunities: Patent Expirations for Major Drugs, U.S., 2011-2016 56Life Sciences Trends and Opportunities: Patent Expirations for Top Biologics, U.S., 2011-2019 57Life Sciences Trends and Opportunities: Top M&A Deals, U.S., 2011-2016 59

To order this report: Global Life Sciences Trends and Opportunities 2012-2015

__________________________Contact Clare: clare@reportlinker.com US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs